Featured Events
Altin CEO Sue McKinney spoke at HERS – Health Executives Research Symposium, San Diego, CA
March 23, 2026
The FDA’s Botanical Drug Guidance offers drug developers a regulatory pathway to approval for plant-based medicines. Plants are sophisticated chemical manufacturing environments and hold therapeutic promise for a multitude of conditions. Altin Biosciences is pursuing a novel botanical therapeutic for the non-hormonal treatment of uterine fibroids. Learn about the regulatory pathway for botanicals, myths, challenges and opportunities.
The Women’s Health Advocates Endometriosis & Adenomyosis Capitol Hill Day
March 10, 2026
The Women’s Health Advocates Endometriosis & Adenomyosis Capitol Hill Day. Altin CEO Sue McKinney joined advocates, clinicians, and patients for a congressional briefing followed by meetings with lawmakers to address research funding, diagnosis, and reimbursement coding for endometriosis. Sue met with health policy representatives from Senators Alex Padilla and Adam Schiff, as well as congressional staff from several states.
HHS Inaugural National Conference on Women’s Health
March 10-12, 2026
Altin CEO Sue McKinney joined over 1,000 participants gathered to hear speakers over three days at the first national conference on women’s health by HHS. FDA Commissioner Marty Makary spoke of the FDA’s removal of the long-standing “black box” warnings from hormone replacement therapy (HRT) products for menopause; and the potential for future availability of topical vaginal estrogen over-the-counter.
Altin meets with Organon, JPMorgan
January 13, 2026
Altin attended an applauded the presentation of Oriana Papin-Zoghbi’s report on “Follow the Exits.” This groundbreaking data was unveiled in the first comprehensive women’s health exit report at JPM 2026, confirming $100B return on women’s health investments in recent years, with 27 $1B exits since 2020, refutes the perception that investment in women’s health is a niche market. 51% of the population is NOT niche. The dollars follow the sense.
JPMorgan Spotlight on Women’s Health: Innovation & Investment with Milken Institute
January 13, 2026
Altin attended an applauded the presentation of Oriana Papin-Zoghbi’s report on “Follow the Exits.” This groundbreaking data was unveiled in the first comprehensive women’s health exit report at JPM 2026, confirming $100B return on women’s health investments in recent years, with 27 $1B exits since 2020, refutes the perception that investment in women’s health is a niche market. 51% of the population is NOT niche. The dollars follow the sense.
New England Venture Summit: Altin Biosciences
December 9, 2025
The 16th annual New England Venture Summit, presented by young Startup Ventures, is the premier industry gathering connecting venture capitalists, corporate VCs, angel investors, technology transfer professionals, senior executives of venture backed, emerging and early stage companies, university researchers, incubators, and premier service providers. Altin Biosciences was selected to pitch for investment to support the research & development of our non-hormonal uterine fibroid drug candidate.
Patented: ABC-105/ABC-205 Non-Invasive, Non-Hormonal Treatment for Uterine Fibroids
December 9, 2025
Uterine fibroids affect a significant percentage of women of reproductive age and are a common contributor to infertility. While surgery is often used to manage fibroids, invasive procedures can carry risks, long recovery times, and high recurrence rates. This article explores research into biologically active compositions, including a cultivar of Crinum latifolium L. and EGCG, being studied as non-surgical approaches for fibroid treatment.
Northeastern University at Mills College
November 13, 2025
Addressing pressing challenges and opportunities in women’s health including: Increasing awareness of conditions affecting millions, from menopause, uterine fibroids, and autoimmune diseases to cardiovascular health. Balancing clinical trials to reflect actual disease prevalence. Closing the investment gap in women’s health research and businesses.
From Entrepreneur to Drug Innovator: Sue McKinney’s Mission to Transform Fibroid Treatment
November 11, 2025
In an interview conducted by Lori Brumat, Sue McKinney shares her unconventional journey—from early entrepreneurship and public service to launching Altin Biosciences. The conversation traces how decades of global trade experience and collaboration with researchers led to the development of a non-hormonal botanical drug candidate aimed at addressing the growing clinical and economic burden of uterine fibroids.
Women’s Health Horizons: The Unseen Impact of Fibroids, Boston
October 16, 2025
Women’s Health Horizons is the only women’s health conference series guided by a global strategic advisory board of more than 30 world-renowned leaders, each with decades of experience in the field. Fibroid panel experts included moderator Cheryl Kerr (formerly Bayer Women’s Health), Dr. Bhuchitra Singh (Johns Hopkins Medicine), Sue McKinney (Altin Biosciences) and Sateria Venable (The Fibroid Foundation).
Treating Uterine Fibroids Without Hormones: Advancing Non-Surgical Innovation
October 16, 2025
Uterine fibroids represent an estimated $42.2 billion annual burden on the U.S. economy, impacting millions of women and families. This panel discussion, sponsored by Northeastern University, explores emerging non-hormonal, botanical drug research and the future of fibroid treatment, featuring perspectives from Altin Biosciences leadership, clinical research, women’s health advocacy, and strategic advisors in the field.
Los Gatos, CA. Meeting of Women’s Health Advocates
September 7, 2025
Uniting people to educate local and national government decision-makers on policies and funding needed to advance the health of women.
Town Hall Meeting, Piedmont, CA. Altin CEO Sue McKinney meets with US Representative Lateefah Simon
August 26, 2025
Altin CEO Sue McKinney meets with US Representative Lateefah Simon, a cosponsor of the Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2025 (H.R.4395). This legislation aims to address uterine fibroids, which are common muscular tumors that cause pain, heavy bleeding, and reproductive issues, particularly impacting minority women.
Press Release: Altin Biosciences Secures U.S. Patent Approval for First-in-Class Non-Hormonal Fibroid Drug Candidate
June 25, 2025
Altin Biosciences has announced U.S. patent approval for its lead non-hormonal, oral botanical drug candidate for uterine fibroids. The patent covers CRILA® and EGCG compositions designed to offer a non-surgical treatment option that may preserve fertility and expand therapeutic choices for patients and clinicians.
Altin Biosciences Highlights Fibroid Research at The White Dress Project Event with Dr. Ayman Al-Hendy
July 15, 2023
During a July 2023 event in Washington, DC hosted by The White Dress Project, Dr. Ayman Al-Hendy was honored for his contributions to women’s health and fibroid research. The event also marked a moment to reflect on recently completed laboratory work at the University of Chicago evaluating non-hormonal botanical components developed for Altin Biosciences’ patented drug candidate.
